INTRODUCTION
============

Diabetes mellitus is a common metabolic disorder that causes economic and social burden worldwide. According to the International Diabetes Federation, the number of people with diabetes is expected to increase from 415 million in 2015 to 642 million by 2040. The prevalence of both type 1 diabetes and type 2 diabetes has increased, and the rising number of people with obesity has resulted in an increasing prevalence of type 2 diabetes worldwide \[[@B1]\].

The pathophysiology of type 2 diabetes is characterized by both impaired insulin action on target tissues and defective pancreatic β-cell insulin secretion in response to glucose \[[@B2]\]. Although both contribute to disease development, the contribution of these factors differs by population. Specifically, type 2 diabetes in East Asia, including South Korea, is characterized primarily by β-cell dysfunction \[[@B3][@B4][@B5][@B6][@B7]\]. However, the prevalence of diabetes has increased in conjunction with the incidence of obesity in South Korea \[[@B8]\], and previous studies have reported that insulin resistance is the dominant factor in the development of type 2 diabetes due to lifestyle changes, including higher dietary intake and decreased physical activity \[[@B9][@B10]\].

Thus, we evaluated the clinical characteristics of insulin resistance and the insulin secretion capacity of newly diagnosed, drug-naive people with type 2 diabetes in 2015 to 2016 by analyzing nationwide cross-sectional data.

METHODS
=======

A cross-sectional study that included 83 primary care clinics and hospitals from different areas in South Korea was conducted. All individuals who visited each clinic or hospital from August 2015 to May 2016 and whose type 2 diabetes had been diagnosed within 1 year, based on the 2011 Korean Diabetes Association guidelines, were included \[[@B11]\]. Exclusion criteria were as follows: age \<19 years; use of diabetes medication; people with type 1 diabetes or gestational diabetes; who received steroid treatments above control levels; or who had a history of cancer, substance abuse, or alcoholism. A total of 924 participants were enrolled in the study. For accurate observation of clinical characteristics, three participants with missing information on glucose levels and nine abnormal values (outliers) were excluded. The remaining 912 participants (512 men and 400 women) were included in the final analysis. The proportion of participants from clinic and hospital was 82.0% and 18.0%, respectively.

Trained interviewers collected demographic and clinical characteristics including age, gender, cigarette smoking status, alcohol consumption status, physical activity, dietary therapy, use of medications, and history of comorbid conditions. Height (m) and weight (kg) were measured, and body mass index (BMI) was calculated as weight (kg) divided by height squared (m^2^). BMI was classified according to Asian-specific criteria \[[@B12]\] as follows: underweight, BMI \<18.5 kg/m^2^; normal weight, BMI 18.5 to 22.9 kg/m^2^; overweight, BMI 23.0 to 24.9 kg/m^2^; obese class I, BMI 25.0 to 29.9 kg/m^2^; and obese class II, BMI ≥30.0 kg/m^2^. Waist circumference was measured at the midpoint between the lower ribs and the iliac crest. Blood pressure was measured by trained staff while the participant was sitting and had rested for at least 5 minutes. Blood samples were obtained after fasting for at least 10 hours, and the following were measured: serum fasting glucose, insulin, C-peptide, glycosylated hemoglobin (HbA1c), triglycerides, total cholesterol, and high density lipoprotein cholesterol (HDL-C). Low density lipoprotein cholesterol (LDL-C) was calculated according to the following formula: LDL-C=total cholesterol--HDL-C--(triglycerides/5) \[[@B13]\]. To allow for the accurate evaluation of glucose metabolism, an oral glucose tolerance test (OGTT) was performed. After 30 minutes of oral glucose loading, a blood sample was taken, and glucose, insulin, and C-peptide levels were analyzed using biochemical assays performed by a central laboratory (Seoul Clinical Laboratories, Seoul, Korea). Insulin resistance was evaluated using the homeostatic model assessment of insulin resistance (HOMA-IR), and β-cell dysfunction was evaluated using the homeostatic model assessment of β-cell function (HOMA-β), fasting C-peptide levels, the insulinogenic index, and the disposition index. HOMA-IR was calculated as fasting insulin (µIU/mL)×fasting glucose (mmol/L)/22.5, and HOMA-β was calculated as 20×fasting insulin (µIU/mL)/\[fasting glucose (mmol/L)--3.5\] \[[@B14]\]. The insulinogenic index was calculated as \[insulin 30 minutes--insulin 0 minute (pmol/L)\]/\[glucose 30 minutes--glucose 0 minute (mmol/L)\]. The disposition index was calculated as insulinogenic index multiplied by 1/fasting insulin \[[@B15]\]. The presence of insulin resistance was defined as a HOMA-IR value ≥2.5 \[[@B16]\]. We categorized insulin secretion by using fasting serum C-peptide levels as follows: severe (\<1.10 ng/mL), moderate (1.10 to 1.69 ng/mL), and mild to non-secretory defect (≥1.70 ng/mL) \[[@B17]\]. The presence of insulin secretory defect was defined as fasting C-peptide levels \<1.70 ng/mL. The presence of metabolic syndrome was determined using the modified National Cholesterol Education Program/Adult Treatment Panel III definition and was defined by the presence of three or more of the following criteria: (1) waist circumference ≥90 cm in men or ≥85 cm in women; (2) triglycerides ≥1.7 mmol/L (150 mg/dL); (3) HDL-C \<1.03 mmol/L (40 mg/dL) in men or \<1.29 mmol/L (50 mg/dL) in women; (4) systolic blood pressure ≥130 mm Hg, diastolic blood pressure ≥85 mm Hg, or use of antihypertensive therapy; and (5) fasting glucose ≥5.6 mmol/L (100 mg/dL) or a previous diagnosis of diabetes \[[@B18]\].

Variables with a skewed distribution were log-transformed before analysis. Descriptive statistics used to characterize the study participants are presented as the mean±standard deviation or the median and interquartile range for continuous variables, and as frequencies and percentages for categorical variables. Differences were analyzed using Student *t*-test, the Mann-Whitney *U* test, or one-way analysis of variance followed by Tukey multiple-comparison test for continuous variables and the chi-square test for categorical variables. All analyses were conducted using the SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA).

Ethical consideration
---------------------

The study protocol was reviewed and approved by the Institutional Review Board (IRB) of Bucheon St. Mary\'s Hospital at the Catholic University (IRB No. HC14OIMI0132) and also by IRBs of all participating institutions. All participants provided written informed consent before participation.

RESULTS
=======

The characteristics of the study participants are shown in [Table 1](#T1){ref-type="table"}. The mean age of the men and women included in this study was 54.3 and 58.8 years, respectively. The median HOMA-IR value in men was significantly higher than that in women (3.6 vs. 3.3). However, the median HOMA-β, insulinogenic index, and disposition index values in men were significantly lower than in women (HOMA-β, 45.9 vs. 68.5; insulinogenic index, 9.7 vs. 21.3; disposition index, 0.15 vs. 0.29). The fasting glucose and 30-minute glucose levels of men were significantly higher than those of women. The median HbA1c in men was also significantly higher than in women. In addition, the proportion of participants with HbA1c ≥10% was 20.7% in men and 9.3% in women. The proportion of participants with current smoking or current drinking status was higher in men than in women (current smoking, 40.0% vs. 4.8%; current drinking, 72.1% vs. 19.3%). On the other hand, the proportion of participants using antihypertensive and lipid-lowering drugs was lower in men than in women (antihypertensive drugs, 36.1% vs. 43.3%; lipid-lowering drugs, 23.6% vs. 35.8%).

[Table 2](#T2){ref-type="table"} shows the characteristics of the study participants according to age groups. Using age categories of \<40 years (*n*=81, 8.9%), 40 to 64 years (*n*=604, 66.2%), and ≥65 years (*n*=227, 24.9%), the proportion of men, the BMI, the waist circumference, and the diastolic blood pressure were highest in the younger participants. In addition, younger participants had significantly higher fasting glucose, 30-minute glucose, fasting insulin, fasting C-peptide, HOMA-IR, and HbA1c levels than the older participants. Moreover, the proportion of participants with HbA1c ≥10% was higher in the youngest age category than in the oldest (42.0% and 7.0% for age groups \<40 years and ≥65 years, respectively). However, the median HOMA-β, insulinogenic index and disposition index values were significantly lower in the younger participants than in the older participants. Younger age was associated with a lower proportion of antihypertensive and dyslipidemia medication use. In addition, the proportion of current smokers and drinkers was highest in the younger participants. However, the proportion of dietary therapy and physical activity was lowest in the younger participants.

[Table 3](#T3){ref-type="table"} shows the distribution of insulin resistance and insulin secretion among the study participants. A total of 4.4% and 18.2% of participants had severe (C-peptide \<1.10 ng/mL) and moderate (C-peptide 1.10 to 1.69 ng/mL) insulin secretory defects, respectively. The proportion of participants with mild to non-secretory defects (C-peptide ≥1.70 ng/mL) was 77.4%. On the other hand, the proportion of participants with insulin resistance (HOMA-IR ≥2.5) was 75.1%. When participants were divided according to both insulin resistance and insulin secretion, the proportion of participants with insulin resistance and mild to non-secretory defect was the greatest (67.4%).

[Fig. 1](#F1){ref-type="fig"} shows the distributions of HOMA-IR, HOMA-β, the insulinogenic index, and the disposition index values according to BMI. As BMI increased, HOMA-IR, HOMA-β, and insulinogenic index increased (*P*\<0.01 for all comparisons). However, there were no differences in the disposition index according to BMI (*P*=0.257).

When the presence of insulin resistance and β-cell dysfunction were defined as HOMA-IR ≥2.5 and fasting C-peptide levels \<1.70 ng/mL, respectively, the proportion of participants with insulin resistance but no β-cell dysfunction increased, and the proportion of participants with β-cell dysfunction but no insulin resistance decreased as BMI increased. In those with BMI more than 30 kg/m^2^, the proportion of participants with insulin resistance but no β-cell dysfunction was the greatest (86.4%) ([Fig. 2A](#F2){ref-type="fig"}). By age groups, the proportion of participants with insulin resistance but no β-cell dysfunction decreased from 72.8% among those younger than 40 years of age to 57.3% among those older than 65 years of age. On the other hand, the proportion of participants with β-cell dysfunction but no insulin resistance increased from 4.9% among those younger than 40 years of age to 22.9% among those older than 65 years of age ([Fig. 2B](#F2){ref-type="fig"}).

DISCUSSION
==========

In this analysis of nationwide cross-sectional data, we observed that insulin resistance plays a more important role than β-cell dysfunction in the pathophysiology of participants with newly diagnosed type 2 diabetes.

Historically, β-cell dysfunction has been described as the main etiological factor underlying type 2 diabetes in East Asia. Insufficient β-cell response to a minor decrease in insulin sensitivity results in loss of glycemic control and increased risk of diabetes \[[@B19]\]. Previous studies have suggested that impaired early-phase insulin secretion is the main factor underlying diabetes development in East Asian countries such as China, Japan, and South Korea \[[@B7][@B20][@B21]\]. In South Korea, approximately 65% of people with type 2 diabetes were not obese in the late 1990s, and β-cell mass was markedly reduced, resulting in impaired and delayed insulin secretion \[[@B22][@B23]\]. Moreover, Ohn et al. \[[@B5]\] reported that β-cell function and impaired β-cell compensation play an important role in the worsening of glucose tolerance in the Ansung-Ansan cohort study, in which the initial enrollment was performed in 2001 to 2002.

However, the prevalence of diabetes is shifting toward younger and more obese populations in South Korea \[[@B8]\]. Obesity is the main factor responsible for the increased risk of developing type 2 diabetes. The increase in obesity due to rapidly westernizing lifestyle habits affects the development of insulin resistance through release of non-esterified fatty acids, glycerol, hormones, and proinflammatory cytokines \[[@B24][@B25][@B26][@B27]\]. In South Korea, previous studies have reported that insulin resistance is the initial abnormality that manifests during the development of type 2 diabetes. Kim et al. \[[@B9]\] reported that in 2005, 70.6% of people with type 2 diabetes had insulin resistance, whereas 46.1% of those with type 2 diabetes had β-cell dysfunction. During 2009 to 2010, 59.5% of drug-naive people with type 2 diabetes were insulin resistant, whereas 20.2% of drug-naive people with type 2 diabetes had β-cell dysfunction \[[@B10]\]. In addition, in our present study, obese participants with type 2 diabetes had relatively more insulin resistance, whereas non-obese participants with type 2 diabetes had relatively more β-cell dysfunction. Specifically, the prevalence of insulin resistance was 86.4% in those with a BMI of 30 kg/m^2^ or greater. These findings are consistent with those of previous studies. In South Korea, 60% of people with type 2 diabetes and a BMI \>23.7 kg/m^2^ were insulin resistant \[[@B28]\]. In China, Liu et al. \[[@B29]\] reported that obese individuals had high HOMA-IR values, but non-obese individuals had low HOMA-β and insulinogenic index values. Ultimately, although β-cell dysfunction is an important contributing factor to the development of type 2 diabetes, it is essential to avoid obesity and insulin resistance for type 2 diabetes prevention.

We observed that people diagnosed before 40 years of age had severe obesity, severe insulin secretion defects, and severe insulin resistance, which triggered early manifestations of hyperglycemia. On the other hand, people who were diagnosed after 65 years of age had relatively mild type 2 diabetes, as well as less severe obesity, insulin secretion defects, insulin resistance, and hyperglycemia. A previous study reported that people with type 2 diabetes diagnosed before 45 years of age were more obese and had poorer glycemic control and more abnormal lipid levels than those diagnosed at or after 45 years of age, using the Kaiser Permanente Northwest Diabetes Registry in the United States. In addition, this study suggests an inverse linear relationship between obesity and age of diabetes onset \[[@B30]\]. Further, a previous study reported that emergency department visits for hyperglycemia were highest among adults aged 18 to 44 years, using data from the Nationwide Emergency Department Sample in the United States \[[@B31]\].

The reasons underlying why young adults diagnosed before 40 years of age were affected with different pathophysiological aspects in the early period of diabetes compared with the older population remain unclear. Early-onset type 2 diabetes is characterized by pancreatic β-cell impairment and obesity-induced insulin resistance \[[@B32]\]. Obesity contributes to an adverse cardiometabolic risk profile, and an abnormal internal environment contributes to the development of early onset of diabetes through hyperinsulinemia with progressive β-cell impairment \[[@B33][@B34][@B35]\]. Further, younger participants may deteriorate insulin secretion by high glucose-induced glucotoxicity \[[@B36]\]. In addition, people diagnosed before 40 years of age had unhealthier lifestyles, including smoking, alcohol consumption, and physical inactivity. Lifestyle- and environmental-related factors such as smoking, alcohol consumption, lack of sleep, physical inactivity, and sedentary behavior cause continuous oxidative stress and thus induce impairments in β-cell function and insulin resistance by negatively affecting insulin signaling \[[@B37][@B38]\]. However, according to the Korea National Health and Nutrition Examination Survey 2013 to 2015, as age decreased, diabetes awareness tended to decrease. In those 30 to 39 years of age, diabetes awareness rate was 42.3%; on the other hand, in those 60 to 69 years of age, diabetes awareness rate was 79.3% \[[@B39]\]. Younger people are less likely to get a health checkup. Therefore, they are likely to be diagnosed with relatively higher HbA1c because they visit the clinic only when they have severe hyperglycemic symptoms.

This study has several limitations. First, it was cross-sectional in nature, and the direction of causality is unclear. It is necessary to evaluate changes in β-cell function and insulin resistance after improved blood glucose control to comprehend characteristics by difference of age, but this study could not do so. Next, we evaluated insulin secretion by using various indices. However, a 75-g OGTT was administered with additional blood samples collected at 30 minutes. Moreover, we did not consider insulin resistance indices such as the Matsuda insulin sensitivity index, which is a more elaborate method of measuring insulin resistance. Finally, the participants were recruited from primary care clinics or hospitals from different areas to represent the general population of South Korea. Although standardized questionnaires and measurement protocols were used, measurement errors may have occurred due to recruitment from multiple sites.

This analysis of nationwide cross-sectional data from South Korea suggested that the main pathogenesis in participants with newly diagnosed type 2 diabetes is insulin resistance. To prevent and better manage type 2 diabetes, it is important to understand the characteristics of people with type 2 diabetes; different therapeutic approaches may be required according to pathophysiological differences. Specifically, people who develop type 2 diabetes at a younger age have the double burden of severe insulin resistance and severe insulin secretory defect and might be more likely to develop microvascular and macrovascular complications. Thus, to ensure early initiation of appropriate diabetes care, implementation of obesity management and screening programs for individuals younger than 40 years of age is warranted.
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###### Characteristics of the study participants by sex

![](dmj-42-137-i001)

  Characteristic                    Men (*n*=512)          Women (*n*=400)        *P* value
  --------------------------------- ---------------------- ---------------------- -----------
  Age, yr                           54.3±11.9              58.8±11.2              \<0.001
  Body mass index, kg/m^2^          25.9±3.4               25.9±4.1               0.949
  Waist circumference, cm^a^        90.3±8.3               86.8±10.4              \<0.001
  Systolic blood pressure, mm Hg    130.2±13.9             129.1±14.2             0.225
  Diastolic blood pressure, mm Hg   81.2±10.4              79.0±9.4               0.001
  Fasting glucose, mg/dL            142.5 (116.0--200.5)   122.0 (106.5--145.5)   \<0.001
  30-Minute glucose, mg/dL          234.0 (196.5--294.5)   212.0 (189.0--246.5)   0.001
  Fasting insulin, μIU/mL           10.1 (7.5--13.3)       10.4 (8.0--14.4)       0.058
  30-Minute insulin, μIU/mL         17.3 (11.4--26.8)      25.9 (16.4--38.4)      \<0.001
  Fasting C-peptide, ng/mL          2.4 (1.8--3.2)         2.3 (1.7--3.1)         0.183
  30-Minute C-peptide, ng/mL        3.5 (2.7--4.9)         4.1 (3.1--5.9)         \<0.001
  Measures of β-cell function                                                     
   HOMA-β                           45.9 (24.9--75.1)      68.5 (41.3--99.1)      \<0.001
   Insulinogenic index              9.7 (3.0--22.7)        21.3 (10.3--37.4)      \<0.001
   Disposition index                0.15 (0.05--0.31)      0.29 (0.14--0.48)      \<0.001
  HOMA-IR                           3.6 (2.7--5.6)         3.3 (2.3--4.9)         0.006
  HbA1c, %                          7.4 (6.4--9.5)         6.6 (6.2--7.6)         \<0.001
  HbA1c                                                                           \<0.001
   \<6.5                            148 (28.9)             175 (43.8)             
   6.5--6.9                         69 (13.5)              76 (19.0)              
   7.0--7.9                         96 (18.8)              66 (16.5)              
   8.0--8.9                         49 (9.6)               22 (5.5)               
   9.0--9.9                         44 (8.6)               24 (6.0)               
   ≥10                              106 (20.7)             37 (9.3)               
  Total cholesterol, mg/dL          200.7±51.4             195.4±43.2             0.009
  HDL-C, mg/dL                      46.9±13.0              53.7±14.2              \<0.001
  LDL-C, mg/dL                      121.2±50.9             113.9±41.2             0.002
  Triglycerides, mg/dL              155.0 (106.0--248.5)   125.0 (91.0--176.5)    \<0.001
  Use of antihypertensive drugs     185 (36.1)             173 (43.3)             0.034
  Use of lipid-lowering drugs       121 (23.6)             143 (35.8)             \<0.001
  Metabolic syndrome^a^             334 (65.7)             259 (65.2)             0.929
  Dietary therapy                   62 (12.1)              64 (16.0)              0.092
  Physical activity                 133 (26.0)             101 (25.3)             0.803
  Current smoker                    205 (40.0)             19 (4.8)               \<0.001
  Current drinker                   369 (72.1)             77 (19.3)              \<0.001

Values are presented as mean±standard deviation, median (interquartile range), or number (%).

HOMA-β, homeostatic model assessment of β-cell function; HOMA-IR, homeostatic model assessment of insulin resistance; HbA1c, glycosylated hemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.

^a^Only 508 men and 397 women were measured.

###### Characteristics of the study participants by age groups

![](dmj-42-137-i002)

  Characteristic                    Age, yr                *P* value                                     
  --------------------------------- ---------------------- ---------------------- ---------------------- ---------
  Age, yr                           33.6±4.9               53.8±6.5               71.0±4.9               \<0.001
  Male sex                          60 (74.1)              356 (58.9)             96 (42.3)              \<0.001
  Body mass index, kg/m^2^          28.7±4.9               25.8±3.6               25.1±3.2               \<0.001
  Waist circumference, cm^a^        94.4±12.6              88.1±9.0               88.4±8.8               \<0.001
  Systolic blood pressure, mm Hg    132.2±15.1             129.2±13.9             130.2±13.9             0.174
  Diastolic blood pressure, mm Hg   84.4±12.4              80.7±10.0              77.5±8.2               \<0.001
  Fasting glucose, mg/dL            172.0 (115.0--251.0)   136.0 (113.0--182.0)   121.0 (109.0--137.0)   \<0.001
  30-Minute glucose, mg/dL          248.0 (203.0--347.0)   228.0 (196.0--283.5)   207.0 (183.0--235.0)   \<0.001
  Fasting insulin, μIU/mL           11.3 (8.0--16.7)       10.2 (7.7--13.7)       9.7 (7.5--12.9)        0.037
  30-Minute insulin, μIU/mL         16.9 (10.8--30.5)      19.9 (12.9--31.5)      23.3 (14.7--33.2)      0.047
  Fasting C-peptide, ng/mL          2.8 (1.8--3.8)         2.4 (1.8--3.1)         2.2 (1.6--3.0)         0.031
  30-Minute C-peptide, ng/mL        4.1 (2.3--5.4)         3.7 (2.8--5.1)         3.9 (3.0--5.7)         0.236
  Measures of β-cell function                                                                            
   HOMA-β                           39.3 (16.3--99.4)      51.7 (28.1--83.2)      64.9 (43.6--93.6)      \<0.001
   Insulinogenic index              10.3 (2.2--28.0)       13.4 (4.9--27.9)       18.7 (8.6--31.6)       0.003
   Disposition index                0.15 (0.03--0.33)      0.19 (0.07--0.37)      0.25 (0.12--0.49)      \<0.001
  HOMA-IR                           5.0 (3.4--6.7)         3.6 (2.6--5.3)         3.0 (2.2--4.2)         \<0.001
  HbA1c, %                          9.2 (6.6--11.2)        7.0 (6.3--8.9)         6.6 (6.1--7.6)         \<0.001
  HbA1c                                                                                                  \<0.001
   \<6.5                            17 (21.0)              199 (32.9)             107 (47.1)             
   6.5--6.9                         9 (11.1)               96 (15.9)              40 (17.6)              
   7.0--7.9                         9 (11.1)               115 (19.0)             38 (16.7)              
   8.0--8.9                         4 (4.9)                50 (8.3)               17 (7.5)               
   9.0--9.9                         8 (9.9)                51 (8.4)               9 (4.0)                
   ≥10                              34 (42.0)              93 (15.4)              16 (7.0)               
  Total cholesterol, mg/dL          222.2±74.1             198.1±44.3             190.6±43.0             \<0.001
  HDL-C, mg/dL                      42.8±10.0              49.6±13.8              53.3±14.4              \<0.001
  LDL-C, mg/dL                      147.0±73.3             117.8±42.7             108.2±41.8             \<0.001
  Triglycerides, mg/dL              155.0 (120.0--300.0)   140.5 (98.5--220.5)    130.0 (98.0--190.0)    0.002
  Use of antihypertensive drugs     13 (16.0)              223 (36.9)             122 (53.7)             \<0.001
  Use of lipid-lowering drugs       18 (22.2)              167 (27.6)             79 (34.8)              0.049
  Metabolic syndrome^a^             60 (75.0)              392 (65.3)             141 (62.7)             0.135
  Dietary therapy                   7 (8.6)                77 (12.7)              42 (18.5)              0.037
  Physical activity                 14 (17.3)              150 (24.8)             70 (30.8)              0.041
  Current smoker                    34 (42.0)              165 (27.3)             25 (11.0)              \<0.001
  Current drinker                   52 (64.2)              321 (53.1)             73 (32.2)              \<0.001

Values are presented as mean±standard deviation, number (%), or median (interquartile range).

HOMA-β, homeostatic model assessment of β-cell function; HOMA-IR, homeostatic model assessment of insulin resistance; HbA1c, glycosylated hemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.

^a^Only 80 people aged \<40 years, 600 people aged 40 to 64 years, and 225 people aged ≥65 years were measured.

###### The proportion of study participants according to insulin resistance and insulin secretion

![](dmj-42-137-i003)

  HOMA-IR   C-peptide levels, ng/mL   Total                     
  --------- ------------------------- ------------ ------------ -------------
  ≥2.5      8 (0.9)                   62 (6.8)     615 (67.4)   685 (75.1)
  \<2.5     32 (3.5)                  104 (11.4)   91 (10.0)    227 (24.9)
  Total     40 (4.4)                  166 (18.2)   706 (77.4)   912 (100.0)

Values are presented as number (%).

HOMA-IR, homeostatic model assessment of insulin resistance.
